Home / Treatments / Osteoporosis Rx
Osteoporosis Rx denials: what the review data shows
Independent reviewers have decided 55 published cases where an insurer denied Osteoporosis Rx — and they overturned the insurer 67.3% of the time. A denial for Osteoporosis Rx is a starting position, not a final answer.
Published decisions
55
2001–2026
Overturned
67.3%
37 denials reversed
Conditions behind osteoporosis rx denials
What insurers denied — and how those fights ended.
| Category | Decisions | Overturned |
|---|---|---|
| Osteoporosis | 51 | 66.7% |
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 52 | 65.4% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 3 | 100% |
Typical time to a decision
13 days
Most land between 7 and 21 days
Handled as urgent
32.7%
Expedited when a delay would cause harm
Recent direction
Falling
78.6% → 64.7% overturned, last three years
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Findings: The physician reviewer found that an enrollee has requested authorization and coverage for Evenity. Current medical literature indicates that the management of male osteoporosis mirrors the management of postmenopausal osteoporosis in women in clinical practice. Researchers explain, “Osteoporosis, a disease classically attributed to postmenopausal women, is underappreciated, underdiagnosed, and undertreated in men. However, it is not uncommon for osteoporotic fractures to occur in men. About 40% of fractures occur in men with an incidence that has increased over the years. After a first fracture, the risk of a subsequent episode, as well as the risk of death, is higher in the male than in the female population.
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for Forteo 20 mcg/dose pen injector. Buerba and colleagues compared the efficacy of the use of either bisphosphonates or Forteo on radiographic and functional outcomes of patients who underwent thoracolumbar spinal fusion. The authors concluded that Forteo was “associated with higher fusion rates than bisphosphonates.” In this patient’s case, there is a documented history of spinal fusion and a current indication for revision surgery. The patient’s provider has recommended treatment with Forteo to enhance the patient’s bone strength and increase of likelihood of hardware placement success during the planned surgery. Furthermore, treatment with Forteo is likely to health improve the patient’s bone mineral density.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Findings: The physician reviewer found that The patient has requested authorization and coverage for Evenity 210 mg syringes. Bandeira and colleagues note, “Monthly subcutaneous dosing of romosozumab reduces the risk of vertebral and clinical fractures in women with postmenopausal osteoporosis, with a favorable balance of benefits and risks.” However, the authors conclude, “Romosozumab is a promising emerging anabolic agent with a novel mechanism of action that may expand the options for treating osteoporotic patients at high risk of fracture.” Paik and Scott report, “In pivotal phase III trials (FRAME and ARCH), 12 months’ once-monthly romosozumab 210 mg significantly reduced vertebral and clinical fracture risk versus placebo and oral alendronate in postmenopausal women with osteoporosis.
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Tymlos. Findings: The American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis reports, “Approved agents with efficacy to reduce hip, nonvertebral, and spine fractures including alendronate, denosumab, risedronate, and zoledronate are appropriate as initial therapy for most osteoporotic patients with high fracture risk.” The guidelines further note that when starting treatment, it is appropriate to stratify patients by level of fracture risk, with those at very high fracture risk requiring more aggressive treatment to achieve an acceptable level of fracture risk.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
How to use this in your appeal
These are outcomes from California’s external review program — an independent physician panel that binds the insurer. Every state has an equivalent process, and internal appeals succeed even more often. Cite the outcome record for Osteoporosis Rxwhen you appeal: reviewers routinely find that denials like yours didn’t hold up.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.